The data was confirmed to VnExpress Thursday by a consultant of the ministry’s Drug Administration Division.
The drug is claimed to have preventive properties and is supposed for individuals who haven’t contracted Covid-19.
Aside from the producer’s assertion, there haven’t been many research on the drug’s medical efficacy,
AstraZeneca, a British-Swedish multinational pharmaceutical and biotechnology firm, had introduced final August that Evusheld is a mixture of two long-acting antibodies obtained from Covid-19 recoveries, tixagevimab and cilgavimab. It had mentioned that the drug had demonstrated a statistically vital discount within the threat of creating symptomatic Covid-19 within the third-stage trial.
A six-month evaluation had discovered that efficacy of the drug was 83 % in comparison with placebo, it mentioned final November.
The primary cargo of Evusheld to Vietnam is anticipated to reach on the finish of this month.
The cargo is made on the premise of a contract for 20,000 doses signed with AstraZeneca by the Vietnam Vaccine Joint Inventory Firm (VNVC) on November 2, 2021.
In Vietnam, the drug, which have to be preserved at minus 2-8 levels Celsius, shall be used at two hospitals: Tam Anh Hanoi and Tam Anh Ho Chi Minh Metropolis.
The prescribed two does are given at one time and the preventive impact is claimed to final six months.
Tran Quang Binh, chief medical director at Tam Anh Basic Hospital in HCMC, mentioned Evusheld “is to guard those that can’t get the Covid-19 vaccine or haven’t generated sufficient antibodies after being absolutely vaccinated.”
He mentioned the hospital will cost VND19 million ($840) for administering the drug, together with administration of two doses and well being checks earlier than and after.
Evusheld has been accepted by the U.S. and Australia for emergency use to forestall Covid-19.
The U.S. Meals and Drug Administration (FDA) granted the license for Evusheld for pre-exposure prophylaxis of Covid-19 in adults and adolescents from 12 with average to extreme immune compromises because of a medical situation or immunosuppressive medicines and who could not mount an satisfactory immune response to Covid-19 vaccination, in addition to these people for whom Covid-19 vaccination will not be really useful.
A report on the AstraZeneca web site quotes Myron J. Levin, Professor of Pediatrics and Medication, College of Colorado College of Medication within the U.S. and principal investigator on the last-stage trial of the drug, as saying: “Hundreds of thousands of individuals within the U.S. and around the globe stay at severe threat for Covid-19 as a result of their immune methods don’t generate a ample immune response, even after receiving all really useful doses of vaccine. Evusheld is an simply administered new possibility that gives long-lasting safety that might assist them return to their on a regular basis lives.”
Ngo Quy Chau, chairman of the Vietnam Respiratory Affiliation, mentioned after receiving Covid-19 vaccines, the physique often acknowledges the antigens contained within the vaccine after which produces them by itself, which is named lively immunity. Nonetheless, some persons are immune-compromised and their physique doesn’t produce sufficient antibodies. Evusheld can be utilized in such circumstances, Chau mentioned.
